Regeneron Pharmaceuticals, Inc. · NASDAQ:REGN
Regeneron Pharmaceuticals — Investor Presentation (August 2022)
21 slides from Regeneron Pharmaceuticals's investor presentation, August 2022
Slide 1: Regeneron Corporate Presentation
Regeneron Corporate Presentation A u g u s t 2 0 2 2 This non-promotional presentation is intended for the investor audience and contains Regeneron investigational - Internal data as well as forward-looking statements; actual results may vary Use Only materially
Slide 2: Note regarding forward-looking statements & non-GAAP financial measures
Note regarding forward-looking statements & non-GAAP financial measures This presentation includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events
Slide 3: Executing on Our Core Competencies, Investing in Regeneron, Looking Ahead
Executing on Our Investing in Looking Ahead Core Competencies Regeneron to the Future Expect to invest ~$3.6 30+ therapeutic #1 prescribed FDA billion into candidates in various stages approved anti-VEGF Research of clinical development treatment for retinal disease Advancing a and best-in-class, De
Slide 4: Delivering Results Across the Organization
Delivering Results Across the Organization Notable R&D Pipeline Advancements sBLA accepted for 16-week dosing regimen in DR FDA approval for pediatric AD (6 mo - 5 yr) FDA approval for EoE (12 yr+) EC approval for pediatric asthma (6 - 11 yr) FDA acceptance of sBLA for PN with priority 2Q 2022 revie
Slide 5: EYLEA: 10+ Years of Patient Impact
EYLEA®: 10+ Years of Patient Impact Extending leadership position based on efficacy and safety that has transformed millions of lives; 55+ million doses administered worldwide since launch Developed using our proprietary Trap technology, development on aflibercept began in 2004 and became Regeneron’
Slide 6: Dupixent: Strong Performance Across All Approved Indications
Dupixent®: Strong Performance Across All Approved Indications With Significant Opportunity For Sustained Growth ~$2.1Bn 2Q 2022 global net product sales Net Product Sales, $Million U.S. ROW +40% $510 Atopic Dermatitis Asthma CRSwNP EoE $485 $426 $406 $1,582 $352 $1,348 $1,326 $1,257 $1,147 2.2M* 975
Slide 7: Dupixent & Itepekimab COPD Phase 3s Underway
Dupixent® & Itepekimab (anti IL-33) COPD Phase 3s Underway Two-pronged approach against uncontrolled, moderate-to-severe COPD Dupixent potential to address Type 2 COPD Achieved prespecified efficacy milestone in interim analysis of Non-Type 2 Type 2 first Ph3 study which triggered second Ph3 study (
Slide 8: Continued Progress & Developments Across Oncology Pipeline
Continued Progress & Developments Across Oncology Pipeline Regeneron positioned to enhance and extend treatment benefit across many cancer settings Dermato-Oncology Non-Small Cell Lung Cancer • First-in-class leading systemic treatment for advanced CSCC; approved in 2L+ advanced BCC • Approved in 1L
Slide 9: Unique Flexibility of Internally-Developed Pipeline Drives Novel Combinations
Unique Flexibility of Internally-Developed Pipeline Drives Potential for Novel and Differentiated Combinations CD3 Bispecifics: “Signal 1” Tumor-Targeted Biparatopics Designed to bridge tumor-associated Designed to disrupt cellular signaling antigens on cancer cells with CD3- and/or deliver a cytoto
Slide 10: Unique Flexibility of Internally-Developed Pipeline Drives Novel Combinations
Unique Flexibility of Internally-Developed Pipeline Drives Potential for Novel and Differentiated Combinations CD3 Bispecifics: “Signal 1” Tumor-Targeted Biparatopics Odronextamab BCMAxCD3 PSMAxCD3 MUC16xCD3 (CD20xCD3) (REGN5458) (REGN4336) (REGN4018) METxMET MET-altered advanced R/R B-NHL, R/R Mult
Slide 11: Key Data Read-Outs Expected Beginning in 2H 2022
Key Data Read-Outs Expected Beginning in 2H 2022 Upcoming Data Disclosure: Tumor Type Initial Indication 2H 2022 2023 2024+ Lymphoma Odronextamab Hematology Multiple myeloma BCMAxCD3 BCMAxCD3 Neoadjuvant CSCC Cemiplimab Adjuvant CSCC Cemiplimab Dermato-oncology Advanced CSCC (2L) Vidutolimod Cemipli
Slide 12: Bispecifics for Heme-Onc Malignancies: Promising Results from Maturing CD3 Programs
Bispecifics for Heme-Onc Malignancies: Promising Results from Maturing CD3 Programs Combinations with costimulatory bispecifics and other agents entering clinic soon Odronextamab REGN5458 (CD20xCD3)* (BCMAxCD3)** Summary – A single, off-the-shelf bispecific, effective in both indolent Efficacy – Ear
Slide 13: Regeneron Technologies Power Our Pipeline: TRAPs, Antibodies and Bispecifics
Regeneron Technologies Power Our Pipeline: TRAPs, Antibodies and Bispecifics xx TARGET VELOCIGENE®️ TURNKEY DISCOVERY & VALIDATION THERAPEUTICS: TRAPs & ANTIBODIES VELOCIMOUSE®️ (BISPECIFICS & Rubine / Marigold / White (Late 2016) COSTIMS) Protein VELOCIMMUNE®️ Expression Sciences TECH Rubine / Mari
Slide 14: Synergistic Collaborations Supercharge Regeneron's Future
Synergistic Collaborations Supercharge Regeneron’s Future Turnkey Genetics Therapeutics Platforms Unlocking capabilities of mouse and Learnings from mouse genetics human genetics through Existing Turnkey Technologies Novel Turnkey Technologies Biologicals Gene Medicines siRNA Genome Gene TRAPs Antib
Slide 15: Regeneron Genetics Medicines
Regeneron Genetics Medicines Powerful resource linking human genetic variation to disease; empowering strategic partnerships to drive the future of medicine World leading human sequencing • ~2M human exomes sequenced • Linked to Electronic Health Records • 110+ collaborations globally Novel Genetics
Slide 16: Regeneron Genetics Medicines
Regeneron is investing in and delivering REGENERON GENETICS technologies well beyond antibodies MEDICINES • 5 genetics medicines programs in the clinic Building the Pipeline for the Future • 3-5 additional potential targets to advance to IND-enabling studies in next 12 months Pre-IND Clinical Develo
Slide 17: Regeneron-Discovered, Approved and Investigational Medicines
Regeneron-Discovered, Approved and Investigational Medicines Across a Wide and Diverse Set of Diseases PHASE 1 PHASE 2 PHASE 3 APPROVED OR AUTHORIZED fianlimab (LAG-3) cemiplimab (PD1) cemiplimab (PD1) ubamatamab (MUC16xCD3) vidutolimod (TLR9) fianlimab (LAG-3) REGN4336 (PSMAxCD3) odronextamab (CD20
Slide 18: Multiple Potential FDA Submissions: 2022-2024+
Multiple Potential FDA Submissions: 2022-2024+ 2022 2023 2024+ EYLEA DUPIXENT* Fianlimab (LAG3) + LIBTAYO Itepekimab (IL-33)* Q16W in NPDR (1H22) ✓ Chronic Inducible Urticaria - Cold Advanced Melanoma Chronic Obstructive Pulmonary Disease EYLEA REGN5458 (BCMAxCD3) REGN4461 (LEPR) REGN1908-1909 (Feld
Slide 19: Key Upcoming Milestones (Next 12 Months)
Key Upcoming Milestones (Next 12 Months) Ophthalmology Solid Organ Oncology • Ph3 data readout for Aflibercept 8mg formulation • Initial data for MUC16xCD3 and METxMET at ESMO 2022 • Submit sBLA for EYLEA in ROP • Updated data for fianlimab (LAG-3) combo with Libtayo in melanoma at • FDA decision fo
Slide 20: Strong Financial Position Enabling Critical Investments
Strong Financial Position Enabling Critical Investments Capital allocation priorities reflect business priorities Internal Investment $1.8B investment in Tarrytown R&D facilities in our world-class R&D capabilities and capital announced in July 2021 expenditures to support sustainable growth Continu
Slide 21: Reconciliation of Non-GAAP Results and Total Revenue Excluding REGEN-COV
Reconciliation of Non-GAAP Results and Total Revenue Excluding REGEN-COV (casirivimab and imdevimab) See slide 2 for additional important information regarding non-GAAP financial measures included in this presentation 21
Regeneron Pharmaceuticals — Investor Presentation (August 2022) on 6ix